Linked Life Data

7193521

Source:http://linkedlifedata.com/resource/pubmed/id/7193521

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
1981-5-28
pubmed:abstractText
Ten evaluable patients with progressive ovarian adenocarcinoma received third-line chemotherapy consisting of weekly cisplatin (cis-diamminedichloroplatinum[II]) at a dose of 1 mg/kg weekly for a maximum of 6 weeks followed by 60 mg/m2 every 3 weeks. There was no life-threatening toxicity. Seven patients (70%) achieved an objective partial response. This is the highest response rate achieved, to date, by third-line chemotherapy in women with advanced ovarian adenocarcinoma. Weekly cisplatin therefore warrants a trial as first-line therapy.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0361-5960
pubmed:author
pubmed:issnType
Print
pubmed:volume
64
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1379-82
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed:year
1980
pubmed:articleTitle
Weekly cis-diamminedichloroplatinum(II): active third-line chemotherapy in ovarian carcinoma--a preliminary report.
pubmed:publicationType
Journal Article